Heterogeneous persistence of Mycobacterium leprae in oral and nasal mucosa of multibacillary patients during multidrug therapy.
Journal
Memorias do Instituto Oswaldo Cruz
ISSN: 1678-8060
Titre abrégé: Mem Inst Oswaldo Cruz
Pays: Brazil
ID NLM: 7502619
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
03
2022
accepted:
16
09
2022
entrez:
19
10
2022
pubmed:
20
10
2022
medline:
22
10
2022
Statut:
epublish
Résumé
Leprosy is curable by multidrug therapy (MDT) treatment regimen ranging from six to 12 months. The variable levels of tolerance and adherence among patients can, however, result in treatment failure and the emergence of drug-resistant strains. Describe the impact of MDT over Mycobacterium leprae viability in patient's oral and nasal mucosa along treatment. Mycobacterium leprae viability was monitored by quantitative polymerase chain reaction (qPCR) quantification of 16S rRNA in lateral and contralateral scrapings of oral and nasal mucosa of 10 multibacillary patients along the initial five months of treatment. The results demonstrated high heterogenicity of M. leprae viability among patients and between nasal and oral samples. Of six patients who presented good adherence and tolerance to the treatment, only four displayed absence of M. leprae viability in both samples three months after the first MDT dose, while for the other two, the absence of M. leprae viability in the oral and nasal cavities was only detected five months after the first dose. We concluded that qPCR of 16S rRNA for the determination of M. leprae viability in nasal and oral scraping samples could represent an interesting approach to monitor treatment efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Leprosy is curable by multidrug therapy (MDT) treatment regimen ranging from six to 12 months. The variable levels of tolerance and adherence among patients can, however, result in treatment failure and the emergence of drug-resistant strains.
OBJECTIVES
OBJECTIVE
Describe the impact of MDT over Mycobacterium leprae viability in patient's oral and nasal mucosa along treatment.
METHODS
METHODS
Mycobacterium leprae viability was monitored by quantitative polymerase chain reaction (qPCR) quantification of 16S rRNA in lateral and contralateral scrapings of oral and nasal mucosa of 10 multibacillary patients along the initial five months of treatment.
FINDINGS
RESULTS
The results demonstrated high heterogenicity of M. leprae viability among patients and between nasal and oral samples. Of six patients who presented good adherence and tolerance to the treatment, only four displayed absence of M. leprae viability in both samples three months after the first MDT dose, while for the other two, the absence of M. leprae viability in the oral and nasal cavities was only detected five months after the first dose.
MAIN CONCLUSIONS
CONCLUSIONS
We concluded that qPCR of 16S rRNA for the determination of M. leprae viability in nasal and oral scraping samples could represent an interesting approach to monitor treatment efficacy.
Identifiants
pubmed: 36259791
pii: S0074-02762022000101129
doi: 10.1590/0074-02760220058
pmc: PMC9575966
pii:
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Leprostatic Agents
0
DNA, Bacterial
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e220058Références
PLoS Negl Trop Dis. 2013 Aug 22;7(8):e2404
pubmed: 24179562
J Clin Microbiol. 2009 Jul;47(7):2124-30
pubmed: 19439537
Clin Infect Dis. 2016 Dec 1;63(11):1412-1420
pubmed: 27558564
J Med Microbiol. 2009 Jun;58(Pt 6):753-759
pubmed: 19429751
J Clin Microbiol. 1993 Mar;31(3):502-6
pubmed: 8458942
Clin Microbiol Infect. 2013 Oct;19(10):970-4
pubmed: 23331372
Front Microbiol. 2020 May 11;11:711
pubmed: 32477280
Lancet Glob Health. 2021 Jan;9(1):e81-e90
pubmed: 33129378
FEMS Immunol Med Microbiol. 2006 Dec;48(3):319-28
pubmed: 17052269
J Med Microbiol. 1977 Feb;10(1):63-8
pubmed: 320339
J Exp Med. 1960 Sep 1;112(3):445-54
pubmed: 19867175
J Clin Microbiol. 2006 Sep;44(9):3154-9
pubmed: 16954241
J Med Microbiol. 2011 Oct;60(Pt 10):1441-1446
pubmed: 21596907
Mem Inst Oswaldo Cruz. 2004 Aug;99(5):509-11
pubmed: 15543415
Med Mal Infect. 2015 Sep;45(9):383-93
pubmed: 26428602
Ophthalmic Res. 2007;39(2):63-8
pubmed: 17287607
Mem Inst Oswaldo Cruz. 2013 Aug;108(5):572-7
pubmed: 23903971
Pathog Glob Health. 2018 Mar;112(2):72-78
pubmed: 29279044
Am J Trop Med Hyg. 2008 Mar;78(3):518-21
pubmed: 18337353
J Clin Microbiol. 1993 Nov;31(11):2947-51
pubmed: 8263180
BMC Infect Dis. 2019 Aug 28;19(1):753
pubmed: 31462296
J Clin Microbiol. 1998 May;36(5):1352-6
pubmed: 9574704
Lancet Glob Health. 2021 Jan;9(1):e8-e9
pubmed: 33338461
Braz J Med Biol Res. 2012 Feb;45(2):153-7
pubmed: 22286535
Lepr Rev. 1974 Jun;45(2):121-34
pubmed: 4608620
Antimicrob Agents Chemother. 1996 Sep;40(9):2137-41
pubmed: 8878595